FIT Biotech Oy (OHEL:FITBIO) Net Margin % : 0.00% (As of Jun. 2018)

View and export this data going back to 2015. Start your Free Trial

What is FIT Biotech Oy Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. FIT Biotech Oy's Net Income for the six months ended in Jun. 2018 was €-1.83 Mil. FIT Biotech Oy's Revenue for the six months ended in Jun. 2018 was €0.00 Mil. Therefore, FIT Biotech Oy's net margin for the quarter that ended in Jun. 2018 was 0.00%.

The historical rank and industry rank for FIT Biotech Oy's Net Margin % or its related term are showing as below:

OHEL:FITBIO' s Net Margin % Range Over the Past 10 Years
Min: -36510 Med: -4908.6 Max: 13080
Current: -35550

OHEL:FITBIO's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -151.78 vs OHEL:FITBIO: -35550.00

FIT Biotech Oy Net Margin % Historical Data

The historical data trend for FIT Biotech Oy's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FIT Biotech Oy Net Margin % Chart

FIT Biotech Oy Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Net Margin %

-2,137.19

-7,680.00

13,080.00

-36,510.00

FIT Biotech Oy Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18
Net Margin %	Get a 7-Day Free Trial				-14,750.00	-	-	-	-

Competitive Comparison of FIT Biotech Oy's Net Margin %

For the Biotechnology subindustry, FIT Biotech Oy's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FIT Biotech Oy's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FIT Biotech Oy's Net Margin % distribution charts can be found below:

* The bar in red indicates where FIT Biotech Oy's Net Margin % falls into.

FIT Biotech Oy Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

FIT Biotech Oy's Net Margin for the fiscal year that ended in Dec. 2017 is calculated as

Net Margin	=	Net Income (A: Dec. 2017 )	/	Revenue (A: Dec. 2017 )
	=	-3.301	/	0
	=	%

FIT Biotech Oy's Net Margin for the quarter that ended in Jun. 2018 is calculated as

Net Margin	=	Net Income (Q: Jun. 2018 )	/	Revenue (Q: Jun. 2018 )
	=	-1.832	/	0
	=	%

FIT Biotech Oy (OHEL:FITBIO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

FIT Biotech Oy Net Margin % Related Terms

Thank you for viewing the detailed overview of FIT Biotech Oy's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

FIT Biotech Oy (OHEL:FITBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FIT Biotech Oy (OHEL:FITBIO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Biokatu 12, Tampere, FIN, FI-33520

Website

http://www.fitbiotech.com

FIT Biotech Oy is a clinical-stage biotechnology company. It is primarily focused on developing antibody therapies for cancer immunotherapy as well as Deoxyribonucleic acid (DNA) vaccines for the prevention of infectious diseases such as Human immunodeficiency virus (HIV). The firm's GTU technology enables the production of antibodies in the human body instead of using industrially manufactured antibodies. The GTU technology platform has various application areas. The group generates revenue through the sales of services related to the HIV vaccine. The organization is based in Finland.

FIT Biotech Oy (OHEL:FITBIO) Headlines

No Headlines